Full-Time

Director, Order-to-Cash

Azenta

Azenta

1,001-5,000 employees

Automated cold-chain sample management and multiomics

Compensation Overview

$174k - $218k/yr

South Plainfield, NJ, USA

Hybrid

Four days on-site per week required.

Bachelor's

Category
Accounting (1)
Required Skills
NetSuite
ERP
Data Visualization
CRM
Salesforce
Oracle

Get referred to Azenta

See people who can refer or advise you

Requirements
  • A bachelor's degree in Finance, Accounting, Business, or a related field is required.
  • At least 10 years of experience in order-to-cash, accounts receivable, billing, collections, shared services, or finance operations is required.
  • At least 5 years of experience leading global, regional, or shared services teams is required.
  • Experience leading in multi-entity, multi-system, global operating environments is required.
  • Experience managing outsourced or business process outsourcing-supported finance operations is required.
  • Experience with enterprise resource planning and customer relationship management platforms, including NetSuite, Oracle, Salesforce, or similar platforms, is required.
  • Experience in service-based, project-based, life sciences, genomics, or laboratory services revenue models is required.
  • Strong financial, operational, and people leadership capability is required.
  • Deep expertise in working capital, cash flow, billing, collections, and accounts receivable management is required.
  • Experience standardizing processes, improving controls, and scaling global operating models is required.
  • Ability to influence across Sales, Operations, Information Technology, Finance, Controllership, Customer Support, and shared services teams is required.
  • Ability to operate in complex, fast-paced, global environments with competing priorities is required.
Responsibilities
  • Lead the end-to-end order-to-cash function, including billing, cash applications, collections, accounts receivable, customer inquiries, quarterly reporting, controls and compliance, and process transformation.
  • Lead a globally blended organization of approximately 20 team members and manage 4–6 functional leaders across billing, collections, cash applications, accounts receivable, and process transformation.
  • Oversee shared services delivery across regions, service towers, service levels, and operational performance metrics.
  • Lead invoice generation and delivery, invoice accuracy, credit memo processing, and automated and manual billing workflows.
  • Oversee customer portal management across multiple platforms and monitor upload performance.
  • Manage billing controls, customer-specific billing requirements, month-end requirements, system exceptions, and third-party order processing.
  • Partner with Sales, Operations, Information Technology, and other organizations to resolve recurring upstream-data issues.
  • Lead internal and shared-services billing teams supporting regional billing requirements.
  • Drive improvements in invoice accuracy, billing cycle times, and customer inquiry management.
  • Develop and execute collections strategy across customer segments, regions, risk profiles, and account ownership models.
  • Own accounts receivable aging performance, overdue balance reduction, collection prioritization, escalation processes, and bad debt exposure management.
  • Coordinate dispute resolution with cross-functional organizations to accelerate collections.
  • Manage order-hold processes to balance business risk and customer satisfaction.
  • Manage collector teams to drive portfolio optimization and increase collection effectiveness.
  • Improve days sales outstanding, dispute aging, collector productivity, activity and commitment documentation, cash forecast reliability, and customer outreach discipline.
  • Oversee timely and accurate cash applications across automated clearing house, wire, credit card, lockbox, and electronic payment channels.
  • Design and implement an end-to-end unapplied cash management process.
  • Drive enhancements to reduce intercompany journal processes for shared customer payments.
  • Lead shared-services cash application teams with internal process ownership and cross-functional collaboration.
  • Drive improvements in cash posting accuracy, unapplied cash reduction, credit card processing, and automation initiatives.
  • Lead global order-to-cash process standardization across billing, collections, cash application, customer inquiries, reporting, and shared services delivery.
  • Guide insourcing activities to reshore activities currently performed in a shared-services environment.
  • Assess current-state process and system gaps and design future-state standardized workflows to enhance order-to-cash performance.
  • Lead a lean transformation and process excellence team working through a matrixed model with Information Technology, Finance, Operations, Sales, Customer Support, and shared services.
  • Deliver measurable improvements in automation, invoice cycle time, days sales outstanding, unapplied cash, dispute aging, productivity, and sustainable process adoption.
  • Standardize global order-to-cash processes, controls, roles, handoffs, and escalation paths.
  • Reduce manual workflows, customer portal fragmentation, spreadsheet dependency, and regional process variation.
  • Implement scalable playbooks, automation opportunities, dashboards, and continuous improvement routines.
  • Partner with Sales on pricing, contract clarity, deal terms, billing requirements, and customer escalations.
  • Collaborate with Customer Support to resolve billing disputes, credits, payment issues, and customer experience concerns.
  • Work with Laboratory Operations to align order completion, billing triggers, service delivery timing, and issue resolution.
  • Partner with Information Technology to improve system integration, workflow automation, data quality, and reporting across customer relationship management, order tools, and enterprise resource planning platforms.
  • Coordinate with Finance and Controllership on revenue recognition, close activities, audit readiness, and control compliance.
  • Define and execute the global order-to-cash operating model, service delivery structure, governance cadence, and performance expectations.
  • Build functional leadership capability, accountability, and succession strength across order-to-cash teams.
  • Own days sales outstanding, accounts receivable aging, overdue balances, bad debt exposure, collections effectiveness, and cash conversion performance.
  • Drive measurable improvements in working capital through collections, dispute resolution, billing accuracy, and cash application performance.
  • Develop customer segmentation, key performance indicator reporting, and operating rhythms aligned to the business model.
  • Improve process integration across customer relationship management, order management tools, enterprise resource planning, banking, customer portals, and reporting platforms.
  • Strengthen upstream data quality to reduce billing errors, downstream rework, disputes, and cash application exceptions.
  • Partner with Information Technology to prioritize system enhancements, automation, workflow controls, and reporting improvements.
  • Strengthen billing, accounts receivable, cash application, credit memo, and dispute management controls.
  • Ensure alignment with revenue recognition requirements, audit standards, close timelines, and internal control expectations.
  • Balance process efficiency with control rigor, documentation, and accountability.
Desired Qualifications
  • Improved days sales outstanding, accounts receivable aging, cash conversion, and working capital performance.
  • Higher invoice accuracy, faster billing cycle times, and reduced unbilled revenue.
  • Reduced manual workload, portal fragmentation, unapplied cash, and dispute aging.
  • Standardized global order-to-cash playbooks, controls, key performance indicators, and operating cadences.
  • Successful transition from an outsourced model to local operation.
  • Improved customer billing, payment, and issue resolution experience.

Azenta provides end-to-end life sciences solutions focused on sample management and genomic services. Its SMS segment offers automated ultra-cold storage, cryogenics, consumables, instruments, and repository services, while the Multiomics segment (GENEWIZ) provides genomic services like sequencing and gene synthesis. The company integrates hardware, consumables, software, and biorepository capabilities to collect, store, and analyze samples across pharma, biotech, academia, and healthcare, with about 55% recurring revenue. Its goal is to speed up drug development, clinical research, and advanced cell therapies by maintaining sample integrity from collection to data analysis.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Burlington, Massachusetts

Founded

1978

Get referred to Azenta

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 4, 2026 revenue rose 12% to $161 million; guidance reached $613-$618 million.
  • Azenta completed a $50 million buyback and still held $200 million authorization on June 30, 2026.
  • B Medical Systems closed July 1, 2026, sharpening focus on core life-sciences businesses.

What critics are saying

  • May 5, 2026 goodwill impairment exposed Multiomics weakness and triggered securities investigations.
  • Automated Stores rework and North America order softness keep margins and bookings volatile through 2026.
  • If Multiomics keeps missing, Azenta's 2029 plan slips again and acquisitions lose strategic logic.

What makes Azenta unique

  • Azenta owns recurring biorepositories, consumables, and multiomics, reducing pure project dependence.
  • UK Biocentre, acquired March 4, 2026, deepens Europe sample-storage density and automation reach.
  • Its 4titude PCR and custom manufacturing serve diagnostic-kit workflows with ISO 13485 quality.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Company News

Scientist Live
Aug 18th, 2026
Azenta Life Sciences' custom PCR solutions for diagnostic kit manufacturers.

Azenta Life Sciences' custom PCR solutions for diagnostic kit manufacturers. Published: 18 August 2026 Expanding on its 4titude portfolio of PCR products, Azenta Life Sciences has built a reputation for partnering with diagnostic kit manufacturers to develop consumables tailored to their specific workflows As molecular diagnostics drive advances in healthcare, manufacturers are under mounting pressure to provide high-quality, scalable diagnostic kits while meeting stringent requirements. Not all applications are soluble using off-the-shelf solutions. Azenta Life Sciences offers customised molecular diagnostic solutions to support these evolving needs. The solutions combine proven PCR consumables with bespoke design and manufacturing expertise. Whether adapting existing products or creating custom solutions, the company provides flexible options across PCR plates, sealing materials, sample tracking, and automation-compatible consumables to help customers enhance reproducibility, simplify manufacturing, and accelerate product development. Baskar Anand, global product manager, Azenta, said, "Its customisation capabilities extend from concept through to production. Customers can specify plate formats, frame and well colours, coatings, surface treatments, seal materials, printing, chemical compatibility, and barcode or 2D coding options, alongside contract manufacturing to create solutions that exactly fit your application. "Our customers need more than a catalogue of consumables - they need solutions designed around their manufacturing processes. By combining high-quality products with flexible customisation, we're helping diagnostic kit manufacturers build workflows that are efficient, reproducible, and ready to scale." Azenta works with manufacturers to develop customised solutions for applications such as infectious disease diagnostics, supporting automated reagent dispensing, secure heat sealing, sample traceability, and compatibility with downstream analytical platforms. Azenta manufactures custom products in ISO 9001- and ISO 13485-certified facilities, providing the quality systems, consistency, and supply reliability that a diagnostic kit manufacturer requires.

Yahoo Finance
Aug 13th, 2026
Azenta beats Q2 expectations with $161M revenue, up 12% on biorepository growth

Azenta exceeded Wall Street expectations in its second quarter, posting revenue of $161.2 million against estimates of $149.2 million and adjusted earnings per share of $0.16 versus the anticipated $0.10. The company reported 12% year-on-year revenue growth. CEO John Marotta attributed the outperformance to robust growth in biorepositories and consumables segments, alongside improved execution in Multiomics, particularly in Europe and China. Adjusted EBITDA reached $18.46 million, beating analyst estimates of $16.4 million. During the earnings call, analysts focused on sustainability of the North American recovery, order trends, and capital equipment conversion. Marotta noted strong growth in China and Europe but highlighted ongoing challenges in North America's capital equipment market. The company is transitioning from customised to configurable systems whilst maintaining a disciplined approach to capital allocation and mergers and acquisitions.

Yahoo Finance
Aug 7th, 2026
Azenta raises 2026 guidance and completes $50M buyback after swinging to profit

Azenta reported third-quarter revenue of $161.18 million, up from $143.86 million year-over-year, and swung to a quarterly net income of $2.46 million from a net loss. The company raised full-year revenue guidance to $613–$618 million and completed a $50 million share buyback of 2.3 million shares. Despite the quarterly improvement, Azenta still reported a net loss of $173.77 million over the first nine months of fiscal 2026, higher than the previous year. The combination of improving quarterly profitability and the sizeable buyback signals management's focus on operational improvement and disciplined capital allocation. The narrative projects $685 million revenue and $37.8 million earnings by 2029, requiring 4.7% yearly revenue growth.

International Labmate Limited
Jun 1st, 2026
Collaboration advances sustainable laboratory workflows.

Collaboration advances sustainable laboratory workflows. 01 Jun, 2026 Azenta Life Sciences Azenta Life Sciences has entered a collaboration with PulpFixin(R) to help laboratories cut plastic waste while maintaining high standards of performance, traceability, and operational efficiency. The partnership combines Azenta's expertise in sample management and laboratory automation with PulpFixin's AutoRack, a 100% recyclable storage platform designed to support sustainability at scale without requiring major workflow changes, automation revalidation, or disruption to existing sample management processes. Michael Bussmann, Vice President and General Manager of Consumables and Instruments at Azenta, said the company is focused on enabling more environmentally responsible laboratory operations while helping customers progress toward their sustainability targets. "We've already taken steps in this direction, including offering SBS racks made with 90% recycled content, and we continue to look for ways to expand lower-impact options across our portfolio," he said. "By combining PulpFixin's biodegradable rack platform with established FluidX sample management workflows, we're enabling laboratories to reduce reliance on conventional plastic consumables while maintaining compatibility with automation systems, sample integrity, cold-chain performance and operational scalability." Chad Jenkins, CEO of PulpFixin, said the collaboration reflects a shared commitment to improving laboratory sustainability without adding operational burden. "Azenta has consistently demonstrated leadership in helping laboratories modernize operations while addressing evolving expectations around sustainability," he said. "Together, we aim to deliver scalable sample management solutions that reduce the hidden costs associated with plastic waste disposal, recycling logistics and sustainability reporting requirements across laboratory operations." More information online

Yahoo Finance
May 22nd, 2026
Azenta falls 23% after revenue miss leads drug development stocks' mixed Q1 results

Azenta, which provides biological sample management and genomic services for pharmaceutical companies, reported Q1 revenues of $144.8 million, up 1% year on year but missing analyst expectations by 2.5%. The company delivered the weakest performance against analyst estimates amongst eight drug development inputs and services stocks tracked. The sector as a group reported satisfactory Q1 results, with revenues beating consensus estimates by 1.6%, though share prices have declined 2.5% on average since earnings. West Pharmaceutical Services, which manufactures packaging and delivery devices for injectable drugs, posted the strongest Q1 performance in the group. Azenta's stock has fallen 23.4% since reporting earnings and currently trades at $17.65.